ClinicalTrials.gg

Program

Epinephrine

Also written as “epinephrine inhalation aerosol”, “Epinephrine Nasal Spray, 2.5 mg” and “Epinephrine Nasal Spray, 5.25 mg”.

Its studies are mostly in Anaphylaxis · Asthma · Hypersensitivity · Chronic Urticaria · Respiratory Tract Infections, led by 7 companies.

Furthest: phase 4, since Dec 19, 201916 company-led studies, 5 open or runningNext primary completion: Apr 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amphastar Pharmaceuticals40 open or runningphase 4since Dec 19, 2019Jun 7, 2010none ahead
Nasus Pharma42 open or runningphase 3since Jun 8, 2025Dec 1, 2020none ahead
ARS Pharmaceuticals32 open or runningphase 4since Feb 18, 2025Jun 9, 2021Apr 2027phase 4 · NCT06834165
De Motu Cordis20 open or runningphase 1since Nov 9, 2021Nov 9, 2021none ahead
ALK-Abelló10 open or runningphase 4since Jun 20, 2013Jun 20, 2013none ahead
Hikma Pharmaceuticals11 open or runningphase 2since Aug 18, 2026Aug 18, 2026May 8, 2027phase 2 · NCT07891780
Smith & Nephew10 open or runningphase 2since Apr 5, 2017Apr 5, 2017none ahead

Also a collaborator on its studies: medistat-ltd-israel, pharma-medica-research-inc and novotech-australia-pty-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Jun 7, 2010.

  1. Nov 15, 2011Phase 3 study in AsthmaAmphastar Pharmaceuticals · NCT01476904 · 208 enrolled · United States
  2. Jun 20, 2013ALK-Abelló's first study: phase 4 study in Handling of Auto-injectorsNew to ALK-AbellóALK-Abelló · NCT01887405 · 91 enrolled · Sweden
  3. Apr 5, 2017Smith & Nephew's first study: phase 2 study in Healthy VolunteerNew to Smith & NephewSmith & Nephew · NCT03119181 · 40 enrolled · United States
  4. Dec 19, 2019Phase 4 study in AsthmaAmphastar Pharmaceuticals · NCT04207840 · 28 enrolled · United States
  5. Dec 1, 2020Nasus Pharma's first study: phase 1 study in AnaphylaxisNew to Nasus PharmaNasus Pharma · NCT04696822 · 12 enrolled · Israel
  6. Jun 9, 2021ARS Pharmaceuticals's first study: phase 1 study in Respiratory Tract InfectionsNew to ARS PharmaceuticalsARS Pharmaceuticals · NCT04930900 · 15 enrolled · Australia
  7. Nov 9, 2021De Motu Cordis's first study: phase 1 study in AnaphylaxisNew to De Motu CordisDe Motu Cordis · NCT05152901 · 23 enrolled · Australia
  8. Aug 22, 2023Phase 1 study in AnaphylaxisDe Motu Cordis · NCT06013150 · 24 enrolled · Australia
  9. Dec 18, 2023Phase 2 study in AnaphylaxisNasus Pharma · NCT06205134 · 12 enrolled · Israel
  10. Feb 18, 2025Phase 4 study in HypersensitivityARS Pharmaceuticals · NCT06834165 · 600 planned · United States
  11. Apr 4, 2025Phase 2 study in Chronic UrticariaARS Pharmaceuticals · NCT06927999 · 42 planned · United States, Germany
  12. Jun 8, 2025Phase 3 study in Anaphylaxis FoodNasus Pharma · NCT07045701 · 30 planned · Israel
  13. Nov 6, 2025Phase 2 study in AnaphylaxisNasus Pharma · NCT07228325 · 50 planned · Canada
  14. Aug 18, 2026Hikma Pharmaceuticals's first study: phase 2 study in Hypersensitivity, ImmediateNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT07891780 · 44 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 4 study in HypersensitivityARS Pharmaceuticals · NCT06834165
  2. May 8, 2027Primary completion: phase 2 study in Hypersensitivity, ImmediateHikma Pharmaceuticals · NCT07891780
  3. Jun 2027Primary completion: phase 2 study in Chronic UrticariaARS Pharmaceuticals · NCT06927999

TargetBeta

“Adrenergic receptor agonist; Adrenergic receptor agonist”ChEMBL 37, by rule

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07891780Hypersensitivity, Immediate · United States2Not yet recruitingHikma PharmaceuticalsMay 8, 202744
NCT07228325Anaphylaxis · Canada2By invitationNasus PharmaMar 202650
NCT07045701Anaphylaxis Food · Israel3By invitationNasus PharmaJun 12, 202630
NCT06927999Chronic Urticaria · United States, Germany2RecruitingARS PharmaceuticalsJun 202742
NCT06834165Hypersensitivity · United States4RecruitingARS PharmaceuticalsApr 2027600
NCT06205134Anaphylaxis · Israel2CompletedNasus PharmaFeb 2, 202412
NCT06013150Anaphylaxis · Australia1CompletedDe Motu CordisDec 15, 202324
NCT05152901Anaphylaxis · Australia1CompletedDe Motu CordisJun 6, 202223
NCT04930900Respiratory Tract Infections · Australia1CompletedARS PharmaceuticalsMar 31, 202215
NCT04696822Anaphylaxis · Israel1CompletedNasus PharmaSep 28, 202112
NCT04207840Asthma · United States4CompletedAmphastar PharmaceuticalsDec 20, 201928
NCT03119181Healthy Volunteer · United States2CompletedSmith & NephewMay 11, 201740
NCT01887405Handling of Auto-injectors · Sweden4CompletedALK-AbellóSep 201291
NCT01476904Asthma · United States3CompletedAmphastar PharmaceuticalsApr 2012208
NCT01357642Asthma · United States3CompletedAmphastar PharmaceuticalsNov 2011373
NCT01143051Asthma · United States2CompletedAmphastar PharmaceuticalsJun 201024

How it is read

Names in the registry

  • “epinephrine inhalation aerosol”, 4 entries
  • “Epinephrine Nasal Spray, 2.5 mg”, 1 entry
  • “Epinephrine Nasal Spray, 5.25 mg”, 1 entry
  • “0.5 mg epinephrine”, 1 entry
  • “1 mg epinephrine”, 1 entry

Codes read as this program: FMXIN002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.